Quadrant Capital Group’s Denali Therapeutics DNLI Stock Holding History

Quadrant Capital Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-758	Closed	-$14.6K	–	1605
2026 Q1	$14.6K	Hold	758	–	–	﹤0.01%	2102
2025 Q4	$12.5K	Sell	758 -24	-3%	-$405	﹤0.01%	2147
2025 Q3	$11.4K	Buy	+782	New	+$11.2K	﹤0.01%	2126
2025 Q2	–	Sell	-515	Closed	-$7K	–	1692
2025 Q1	$7K	Buy	+515	New	+$9.87K	﹤0.01%	2287
2024 Q1	–	Sell	-19	Closed	-$408	–	2737
2023 Q4	$408	Buy	19 +12	+171%	+$238	﹤0.01%	2632
2023 Q3	$145	Buy	+7	New	+$178	﹤0.01%	2662
2023 Q1	–	Sell	-40	Closed	-$1.11K	–	2741
2022 Q4	$1.11K	Sell	40 -10	-20%	-$298	﹤0.01%	2526
2022 Q3	$2K	Buy	+50	New	+$1.63K	﹤0.01%	2361
2021 Q4	–	Sell	-3	Closed	–	–	2547
2021 Q3	$0	Buy	+3	New	+$169	﹤0.01%	2532

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's DNLI Position: Q2 2026 in Review

Quadrant Capital Group sold out of Denali Therapeutics (DNLI) in Q2 2026, closing a stake of 758 shares — an estimated $14.6K sold.

Quadrant Capital Group first reported a position in DNLI in Q3 2021 and held it in 9 quarters. The position peaked at $14.6K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Quadrant Capital Group reported no remaining Denali Therapeutics position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 758 Denali Therapeutics shares in Q2 2026, an estimated $14.6K.
Quadrant Capital Group first reported a position in Denali Therapeutics in Q3 2021 and held it in 9 quarters.
Quadrant Capital Group's Denali Therapeutics position peaked at $14.6K in Q1 2026.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.